One day after the last drug administration, mice were sacrificed and tumors were harvested; curves of tumor volumes showed that in xenografts harboring K-RAS mutation, in particular in the EGI-1 xenografts, Trametinib drastically slowed the tumor growth down (p <0.0001) (Figure 2A and 2D) compared to the control arm. The gene discussed is KRAS; the disease is neoplasm.